Results 11 to 20 of about 30,694,151 (287)

L-Dopa and Schizophrenia [PDF]

open access: yesCanadian Psychiatric Association Journal, 1976
Previous reports have emphasized the deterioration of schizophrenic patients when given L-Dopa. The authors described a patient with long-standing catatonic schizophrenia who was not helped by conventional therapies but initially responded dramatically to L-Dopa.
P E, Garfinkel, H C, Stancer
openaire   +3 more sources

L-Dopa and the albino riddle: content of L-Dopa in the developing retina of pigmented and albino mice. [PDF]

open access: yesPLoS ONE, 2013
The absence or deficiency of melanin as in albinos, has detrimental effects on retinal development that include aberrant axonal projections from eye to brain and impaired vision. In pigmented retinal pigment epithelium (RPE), dihydroxyphenalanine (L-Dopa)
Suzanne Roffler-Tarlov   +4 more
doaj   +3 more sources

Polymorphism of the Dopa-Decarboxylase Gene Modifies the Motor Response to Levodopa in Chinese Patients With Parkinson's Disease

open access: yesFrontiers in Neurology, 2020
Levodopa (L-DOPA) is the most effective drug for Parkinson's disease (PD). However, the response to L-DOPA remains individually variable, which hampers the practical value of L-DOPA in the clinic. Genetic factors play a role in L-DOPA efficacy.
Lanting Li   +6 more
doaj   +1 more source

Low-dose levodopa protects nerve cells from oxidative stress and up-regulates expression of pCREB and CD39. [PDF]

open access: yesPLoS ONE, 2014
OBJECTIVE: This study aimed to investigate the influence of low-dose levodopa (L-DOPA) on neuronal cell death under oxidative stress. METHODS: PC12 cells were treated with L-DOPA at different concentrations. We detected the L-DOPA induced reactive oxygen
Shi-Ying Zhong   +5 more
doaj   +1 more source

The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets

open access: yesJournal of Pharmacological Sciences, 2023
The adenosine A2A receptor antagonist/inverse agonist, KW-6356 has been shown to be effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to L-3,4-dihydroxyphenylalanine (L-DOPA)/decarboxylase inhibitor.
Yutaro Ohno   +6 more
doaj   +1 more source

Differential Amperometric Microneedle Biosensor for Wearable Levodopa Monitoring of Parkinson’s Disease

open access: yesBiosensors, 2022
Levodopa (L-Dopa) is considered to be one of the most effective therapies available for Parkinson’s disease (PD) treatment. The therapeutic window of L-Dopa is narrow due to its short half-life, and long-time L-Dopa treatment will cause some side effects
Lu Fang   +9 more
doaj   +1 more source

Simultaneous Determination of Levodopa and Carbidopa from Fava Bean, Green Peas and Green Beans by High Performance Liquid Gas Chromatography [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2013
Introduction: According to many studies, sprouted fava beans are a rich source of levo-dihydroxy phenylalanine (L-dopa) the precursor of dopamine, and they are now being investigated for use in the management of Parkinson’s disease.
Mohseni Mehran S.M., Golshani B.
doaj   +1 more source

Effects of Aging on Levo-Dihydroxyphenylalanine- Induced Dyskinesia in a Rat Model of Parkinson’s Disease

open access: yesFrontiers in Aging Neuroscience, 2021
BackgroundIt remains unclear why patients with young-onset Parkinson’s disease more often develop levo-dihydroxyphenylalanine (L-dopa)-induced dyskinesia (LID) and have a more severe form than patients with old-onset Parkinson’s disease. Previous studies
Haruo Nishijima   +8 more
doaj   +1 more source

Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia

open access: yesCells, 2023
Dopamine replacement therapy for Parkinson’s disease is achieved using L-DOPA or dopamine D2/3 agonists, such as ropinirole. Here, we compare the effects of L-DOPA and ropinirole, alone or in combination, on patterns of glial and microvascular reactivity
Osama F. Elabi   +4 more
doaj   +1 more source

Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients

open access: yesGenome Medicine, 2017
Parkinson’s disease (PD) presently is conceptualized as a protein aggregation disease in which pathology involves both the enteric and the central nervous system, possibly spreading from one to another via the vagus nerves.
J. Bedarf   +7 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy